Sovereign 02 vaccine candidate to start clinical trials
The vaccine candidate against Covid-19 called Sovereign 02 was approved by the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) of Cuba to begin phase 1 of clinical trials, the Finlay Institute announced on its Twitter account.
This institution adds in the information that the Sovereign 02 vaccine candidate is based on the countable vaccine platform with precedents at the Finlay Institute, while being an unprecedented drug among all those developed to face SARS-Cov 2.
The director of the FInlay Institute, Vicente Vérez, in a recent interview with the local press said that the novelty of this new candidate consists in being a countable vaccine, in which the virus antigen, the receptor-binding domain (RBD), is chemically bound to tetanus toxoid.
"We hope that the immunity of Soberana 02 reaches the mucosa of the respiratory tract to prevent the entry of the virus, and it will be the vaccine candidate that we will propose to apply in the pediatric population," he said.
Cuba currently has two vaccine candidates in process against Covid-19, Soberana 01 and Soberana 02, molecular drugs or subunit vaccines, according to Vérez.
Soberana 02 will soon begin phase 1 clinical trials on healthy adults, after having completed all the required research phases in laboratory animals, which demonstrated a powerful and effective immune response against the virus.